<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02831712</url>
  </required_header>
  <id_info>
    <org_study_id>13-093</org_study_id>
    <nct_id>NCT02831712</nct_id>
  </id_info>
  <brief_title>Effect of Iron Status on Occurrence of Non-transferrin-bound Iron (NTBI) in Serum in Response to an Oral Iron Load</brief_title>
  <official_title>Effect of Iron Status on Occurrence of Non-transferrin-bound Iron (NTBI) in Serum in Response to an Oral Iron Load</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Walczyk</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National University, Singapore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate a possible effect of iron status on temporary build-up of
      non-transferrin bound iron (NTBI) in healthy volunteers upon iron supplementation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For Visit 1, blood samples will be collected to assess iron status. For Visit 2, after an
      overnight fast, iron supplement will be provided to participant before breakfast. Blood
      samples will be collected right before and 2 h after iron supplement consumption for NTBI
      analysis.

      NTBI concentration before and after iron supplement consumption will be compared. Dependence
      of NTBI formation on markers of iron status (serum iron, transferrin, transferrin saturation,
      serum ferritin and hemoglobin) will be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of NTBI after an oral iron load</measure>
    <time_frame>2 hour post dose</time_frame>
    <description>Blood samples collected 2 h after the iron supplement consumption will be measured for NTBI concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dependence of NTBI concentration on markers of iron status (concentrations of serum iron, serum ferritin, transferrin saturation)</measure>
    <time_frame>2 hour post dose</time_frame>
    <description>Correlation between NTBI concentration and iron status indicators will be evaluated</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Effect of Iron Status on Occurrence of NTBI</condition>
  <arm_group>
    <arm_group_label>Iron supplement</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Ferrous Fumarate tablet 200 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ferrous Fumarate</intervention_name>
    <description>One tablet of a commercial iron supplement (Ferrous Fumarate 200 mg, from Drug House of Australia) will be provided to participants after overnight fast. The intervention is only one time.</description>
    <arm_group_label>Iron supplement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Apparently healthy volunteers (21 - 55 years old)

          -  C-reactive protein (CRP) &lt; 5

        Exclusion Criteria:

          -  Blood donation or significant blood loss (e.g. surgery) within the past 4 months

          -  Regular intake of iron and other nutrient supplements within the past 4 months

          -  Regular intake of medication except oral contraceptives

          -  Acute or recent inflammatory or infectious symptoms

          -  Chronic gastrointestinal disorders or metabolic diseases

          -  Pregnancy or lactation

          -  Coeliac disease or gluten-related disorders

          -  Iron overload conditions (serum ferritin concentration &gt; 200 ng/mL for females, &gt; 300
             ng/mL for males)

          -  Non iron deficiency anemia [serum ferritin concentration within normal range (15-200
             ng/mL for females, 30-300 ng/mL for males) but low hemoglobin (&lt; 12 g/dL for females,
             &lt; 14 g/dL for males)]
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Walczyk, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>National University, Singapore</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National University of Singapore; National University Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <reference>
    <citation>Malyszko J, Głowińska I, Malyszko JS, Levin-Iaina N, Koc-Zorawska E, Mysliwiec M. Iron metabolism in kidney allograft recipients: still a mystery? Transplant Proc. 2011 Oct;43(8):2973-5. doi: 10.1016/j.transproceed.2011.08.055.</citation>
    <PMID>21996204</PMID>
  </reference>
  <reference>
    <citation>Inati A, Musallam KM, Cappellini MD, Duca L, Taher AT. Nontransferrin-bound iron in transfused patients with sickle cell disease. Int J Lab Hematol. 2011 Apr;33(2):133-7. doi: 10.1111/j.1751-553X.2010.01224.x.</citation>
    <PMID>21382180</PMID>
  </reference>
  <reference>
    <citation>Ounjaijean S, Westermarck T, Partinen M, Plonka-Poltorak E, Kaipainen P, Kaski M, Fucharoen S, Srichairatanakool S, Atroshi F. Increase in non-transferrin bound iron and the oxidative stress status in epilepsy patients treated using valproic acid monotherapy. Int J Clin Pharmacol Ther. 2011 Apr;49(4):268-76. doi: 10.5414/CP201466.</citation>
    <PMID>21429441</PMID>
  </reference>
  <reference>
    <citation>Prakash M, Upadhya S, Prabhu R. Serum non-transferrin bound iron in hemodialysis patients not receiving intravenous iron. Clin Chim Acta. 2005 Oct;360(1-2):194-8.</citation>
    <PMID>15979061</PMID>
  </reference>
  <reference>
    <citation>Yegin ZA, Paşaoğlu H, Aki SZ, Özkurt ZN, Demirtaş C, Yağci M, Acar K, Sucak GT. Pro-oxidative/antioxidative imbalance: a key indicator of adverse outcome in hematopoietic stem cell transplantation. Int J Lab Hematol. 2011 Aug;33(4):414-23. doi: 10.1111/j.1751-553X.2011.01297.x. Epub 2011 Feb 10.</citation>
    <PMID>21310008</PMID>
  </reference>
  <reference>
    <citation>Duca L, Da Ponte A, Cozzi M, Carbone A, Pomati M, Nava I, Cappellini MD, Fiorelli G. Changes in erythropoiesis, iron metabolism and oxidative stress after half-marathon. Intern Emerg Med. 2006;1(1):30-4.</citation>
    <PMID>16941810</PMID>
  </reference>
  <reference>
    <citation>Trumbo P, Yates AA, Schlicker S, Poos M. Dietary reference intakes: vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc. J Am Diet Assoc. 2001 Mar;101(3):294-301.</citation>
    <PMID>11269606</PMID>
  </reference>
  <reference>
    <citation>Monsen ER, Hallberg L, Layrisse M, Hegsted DM, Cook JD, Mertz W, Finch CA. Estimation of available dietary iron. Am J Clin Nutr. 1978 Jan;31(1):134-41.</citation>
    <PMID>619599</PMID>
  </reference>
  <reference>
    <citation>Papanikolaou G, Pantopoulos K. Iron metabolism and toxicity. Toxicol Appl Pharmacol. 2005 Jan 15;202(2):199-211. Review.</citation>
    <PMID>15629195</PMID>
  </reference>
  <reference>
    <citation>Hutchinson C, Al-Ashgar W, Liu DY, Hider RC, Powell JJ, Geissler CA. Oral ferrous sulphate leads to a marked increase in pro-oxidant nontransferrin-bound iron. Eur J Clin Invest. 2004 Nov;34(11):782-4.</citation>
    <PMID>15530152</PMID>
  </reference>
  <reference>
    <citation>Baron J, Ben-David G, Hallak M. Changes in non-transferrin-bound iron (NTBI) in pregnant women on iron supplements. Eur J Obstet Gynecol Reprod Biol. 2008 Oct;140(2):281-2. doi: 10.1016/j.ejogrb.2008.01.002. Epub 2008 Mar 4.</citation>
    <PMID>18304722</PMID>
  </reference>
  <reference>
    <citation>Schümann K, Kroll S, Romero-Abal ME, Georgiou NA, Marx JJ, Weiss G, Solomons NW. Impact of oral iron challenges on circulating non-transferrin-bound iron in healthy Guatemalan males. Ann Nutr Metab. 2012;60(2):98-107. doi: 10.1159/000336177. Epub 2012 Mar 6.</citation>
    <PMID>22398912</PMID>
  </reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2016</study_first_submitted>
  <study_first_submitted_qc>July 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2016</study_first_posted>
  <last_update_submitted>July 15, 2016</last_update_submitted>
  <last_update_submitted_qc>July 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>National University, Singapore</investigator_affiliation>
    <investigator_full_name>Thomas Walczyk</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>NTBI</keyword>
  <keyword>Iron status</keyword>
  <keyword>Iron supplement</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
    <mesh_term>Ferrous fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

